Verthermia to Present at the 2016 BIO Investor Forum

Verthermia, Inc., a whole body hyperthermia medical device leader commercializing safe and effective complementary treatments for solid tumor cancer in the metastatic phase, announces that CEO Steve Scott will present at the 2016 BIO Investor Forum taking place October 18-19, 2016 in San Francisco.
 
Heatt system for solid tumor cancers from Verthermia
Heatt system for solid tumor cancers from Verthermia
SAN DIEGO - Oct. 15, 2016 - PRLog -- Conference Presentation Details:

Where:  Westin St. Francis Hotel, 335 Powell St, San Francisco, CA 94102

When:  Wednesday, October 19, 2016 at 9:00AM PDT

Room:  Yorkshire

Conference Website:  https://www.bio.org/events/bio-investor-forum

Currently, the company has limited availability to schedule one-on-one meetings with institutional investors. To schedule a meeting, please contact Steve Scott steve.scott@verthermia.com.

About Verthermia, Inc.

Verthermia, based in California, develops the only effective cancer treatment which induces whole body hyperthermia (WBH) by directly heating and cooling the body core evenly and consistently, branded as Hyperthermic Extracorporeal Applied Tumor Therapy - HEATT™.

Answering the call for the fourth modality in cancer treatment, the company provides equipment and disposables for the treatment of cancer, either alone or as an adjunct to chemotherapy and radiation. Technologies are based on founders' prior experiences using WBH to treat lung cancer, ovarian cancer and infectious diseases (HIV/AIDS). Currently engaged in an FDA approved metastatic ovarian cancer Phase I clinical trial. First patients' trials were completed in San Jose, CA with next trials moving ahead at the Cleveland Clinic.

Expected approval and product launch in 12 to 18 months with over 100 major cancer centers expected to rapidly adopt the technology.

For more information, please visit http://verthermia.com.

About BIO and the BIO Investor Forum

BIO, the Biotechnology Innovation Organization, is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

The BIO Investor Forum is an international biotechnology investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-one Partnering™ meetings.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

End
Source: » Follow
Email:***@verthermia.com Email Verified
Tags:Oncology, Medical Device, Ovarian Cancer, Hyperthermia
Industry:Health, Medical
Location:San Diego - California - United States
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share